Results 301 to 310 of about 196,164 (338)

Rituximab

BioDrugs, 2007
An important role for B cells in the immunopathogenesis of rheumatoid arthritis (RA) is recognized. Rituximab is a chimeric murine/human anti-CD20 monoclonal antibody that transiently depletes CD20+ B cells. A single course of rituximab (two intravenous infusions of 1,000mg given two weeks apart) with a stable dose of methotrexate significantly ...
James E, Frampton, Lesley J, Scott
openaire   +2 more sources

Rituximab

Reactions Weekly, 2021
  +7 more sources

Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study

Annals of the Rheumatic Diseases, 2019
Objective To assess the safety and efficacy of rituximab in systemic sclerosis (SSc) in clinical practice. Methods We performed a prospective study including patients with SSc from the European Scleroderma Trials and Research (EUSTAR) network treated ...
M. Elhai, M. Boubaya, O. Distler, V. Smith, M. Matucci-Cerinic, J. J. Alegre Sancho, M. Truchetet, Y. Braun-Moscovici, F. Iannone, P. Novikov, A. Lescoat, E. Siegert, I. Castellví, P. Airó, S. Vettori, E. De Langhe, E. Hachulla, A. Erler, L. Ananieva, M. Krusche, F. López-Longo, J. Distler, N. Hunzelmann, A. Hoffmann-Vold, V. Riccieri, V. Hsu, M. Pozzi, C. Ancuta, E. Rosato, C. Mihai, M. Kuwana, L. Saketkoo, C. Chizzolini, R. Hesselstrand, S. Ullman, Ş. Yavuz, S. Rednic, C. Caimmi, C. Bloch-Queyrat, Y. Allanore   +39 more
semanticscholar   +1 more source

Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin‐4 Antibody Diseases

Annals of Neurology, 2019
To compare response to rituximab (RTX) between adult patients positive for myelin oligodendrocyte glycoprotein (MOG) and aquaporin‐4 (AQP4) antibodies.
Pierre Durozard, A. Rico, C. Boutiere, A. Maarouf, R. Lacroix, S. Cointe, S. Fritz, C. Brunet, J. Pelletier, R. Marignier, B. Audoin   +10 more
semanticscholar   +1 more source

Rotten Rituximab: Rituximab Related ILD

B36. THE GOOD, THE BAD, AND THE UGLY: DRUG TOXICITY CASE REPORTS, 2023
B.S.K.R. Sabbula, V. Mehta, J. Akella
openaire   +1 more source

Rituximab

Reactions Weekly, 2022
  +4 more sources

Rituximab

Reactions Weekly, 2016
  +7 more sources

Rituximab : Mabthera®

Annales de Dermatologie et de Vénéréologie, 2007
H, Lapeyre, P, Joly
openaire   +2 more sources

Rituximab for Uveitis

Ophthalmology, 2011
E. Miserocchi, I. Pontikaki, G. Modorati, F. Bandello, P. Meroni, V. Gerloni   +5 more
openaire   +2 more sources

Rituximab

2003
Pratik, Multani, Christine A, White
openaire   +2 more sources